Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pfizer

24.61
0.0000
Post-market: 24.630.0200+0.08%19:59 EDT
Volume:44.22M
Turnover:1.09B
Market Cap:139.92B
PE:17.79
High:24.96
Open:24.68
Low:24.53
Close:24.61
Loading ...

FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports

MT Newswires Live
·
11 Jul

Delaware Supreme Court sides with Zantac drugmakers over cancer evidence

Reuters
·
11 Jul

Delaware Supreme Court Excludes Expert Testimony From Plaintiffs Suing GSK, Sanofi, Pfizer Over Zantac, in Victory for Drugmakers

THOMSON REUTERS
·
11 Jul

Delaware Supreme Court sides with GSK, Pfizer on expert testimony in Zantac case

TIPRANKS
·
11 Jul

Pfizer’s Cibinqo Study: A Closer Look at Its Market Potential

TIPRANKS
·
11 Jul

Pfizer’s New Study on PF-07985045: A Potential Game-Changer in Cancer Treatment?

TIPRANKS
·
11 Jul

Market Chatter: BioNTech, Pfizer Urge UK Court to Overturn Moderna Vaccine Patent Ruling

MT Newswires Live
·
10 Jul

Pfizer (PFE) Receives a Hold from Morgan Stanley

TIPRANKS
·
10 Jul

Market Chatter: EC President Survives No-Confidence Vote Over Pfizer Vaccine Negotiation Texts

MT Newswires Live
·
10 Jul

Pfizer, Astellas Say Xtandi Shows Favourable Overall Survival in Prostate Cancer Study

MT Newswires Live
·
10 Jul

Pfizer’s xtandi plus leuprolide improves survival in prostate cancer

TIPRANKS
·
10 Jul

BRIEF-Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence

Reuters
·
10 Jul

Pfizer Announces Positive Results from Phase 3 EMBARK Study on XTANDI® for Non-Metastatic Hormone-Sensitive Prostate Cancer

Reuters
·
10 Jul

Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes in Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence

THOMSON REUTERS
·
10 Jul

Pfizer Inc - Xtandi Plus Leuprolide Improves Overall Survival

THOMSON REUTERS
·
10 Jul

Pfizer: No New Safety Signals Were Observed in Analysis, and Safety Results Were Consistent With Demonstrated Safety Profile of Xtandi

THOMSON REUTERS
·
10 Jul

Pfizer: Embark Met Key Secondary Endpoint

THOMSON REUTERS
·
10 Jul

Singapore to Discuss Pharmaceutical Supply Chain Issues With US

Bloomberg
·
10 Jul

Pfizer’s Inclacumab Study: A Promising Step for Sickle Cell Disease Treatment

TIPRANKS
·
10 Jul

Pfizer’s ATGAM Study: A Key Update for Investors

TIPRANKS
·
10 Jul